27Nov/13

Teva Gets Additional Exclusivity for Treanda – Drug Discovery & Development


Drug Discovery & Development

Teva Gets Additional Exclusivity for Treanda
Drug Discovery & Development
… Administration (FDA) has granted orphan drug exclusivity for Treanda through October 2015 for indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
FDA grants Teva’s Treanda orphan drug statusGlobes
Cancer drug Treanda gets orphan status, but that won’t save Teva’s shrinking …FiercePharma
Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release)

all 14 news articles »

27Nov/13

FDA grants Teva's Treanda orphan drug status – Globes


Drug Discovery & Development

FDA grants Teva’s Treanda orphan drug status
Globes
… that the US Food and Drug Administration (FDA) has granted orphan drug exclusivity for Treanda through October 2015 for the treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with …
Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release)
Teva Pharma Reports Addl. Regulatory Exclusivity For TREANDA For InjectionNASDAQ

all 11 news articles »

27Nov/13

Teva Announces Additional Regulatory Exclusivity for TREANDA … – Business Wire (press release)


Drug Discovery & Development

Teva Announces Additional Regulatory Exclusivity for TREANDA …
Business Wire (press release)
TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Important Safety Information.
FDA grants Teva’s Treanda orphan drug statusGlobes
Teva Gets Additional Exclusivity for TreandaDrug Discovery & Development
Cancer drug Treanda gets orphan status, but that won’t save Teva’s shrinking …FiercePharma

all 12 news articles »